Unearthing nature's remedy: An exploration into Lycopodium's medicinal and therapeutic potential
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cholinesterase and Neurodegenerative Diseases · Circadian rhythm and melatonin
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The brief history of complementary, alternative, and integrative medicine terminology and the development and creation of an operational definition10.1016/j.imr.2023.100978 ↗
2. 2001
3. Insight into the characteristics of research published in traditional, complementary, alternative, and integrative medicine journals: a bibliometric analysis10.1186/s12906-021-03354-7 ↗
4. Medical skepticism and the use of complementary and alternative health care providers by patients followed by rheumatologists10.1097/RHU.0b013e31817734cd ↗
5. Academic doctors’ views of complementary and alternative medicine (CAM) and its role within the NHS: an exploratory qualitative study10.1186/1472-6882-7-17 ↗
6. Complementary and alternative medicines for the treatment of hepatitis C: perspectives of users and CAM practitioners10.1155/2020/3932690 ↗
7. Tradition to pathogenesis: a novel hypothesis for elucidating the pathogenesis of diseases based on the traditional use of medicinal plants10.3389/fphar.2021.705077 ↗
8. Pteridophytes (Ferns)
9. A review of the use of pteridophytes for treating human ailments10.1631/jzus.B1600344 ↗
10. Proanthocyanidins: a comprehensive review10.1016/j.biopha.2019.108999 ↗
11. Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer10.1093/carcin/bgy034 ↗
12. Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson's disease10.1016/j.brainres.2014.01.047 ↗
13. Proanthocyanidins, anthocyanins and cardiovascular diseases10.1016/j.foodres.2014.01.046 ↗
14. Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells10.1080/13510002.2018.1462027 ↗
15. 1911
16. Chapter 11 - Homeopathic remedies
17. A better understanding of pharmacological activities and uses of phytochemicals of Lycopodium clavatum: a review
18. Effect of homeopathic Lycopodium clavatum on memory functions and cerebral blood flow in memory-impaired rats10.1016/j.homp.2014.08.003 ↗
19. Hepatoprotective effect of Lycopodium clavatum 30CH on experimental model of paracetamol-induced liver damage in rats10.1016/j.homp.2014.05.005 ↗
20. Five new fawcettimine-related alkaloids from Lycopodium japonicum Thunb10.1016/j.fitote.2013.08.007 ↗
21. Japonicumins A–D: four new compounds from Lycopodium japonicum10.1002/hlca.200690148 ↗
22. Antioxidant and antimicrobial actions of the clubmoss Lycopodium clavatum L10.1007/s11101-006-9053-x ↗
23. The therapeutic effects of seven lycopodium compounds on cell models of Alzheimer's disease10.3233/JAD-220704 ↗
24. The apoptotic effect of the Lycopodium clavatum extracts on MCF-7 human breast cancer cells10.1007/s12032-023-02159-7 ↗
25. Cytotoxic and nitric oxide inhibitory activities of triterpenoids from Lycopodium clavatum L10.1080/14786419.2021.2024824 ↗
26. Natural compounds and their derivatives as multifunctional agents for the treatment of Alzheimer disease
27. The traditional uses, secondary metabolites, and pharmacology of Lycopodium species10.1007/s11101-021-09746-4 ↗
28. Preparation of medicinal plants: basic extraction and fractionation procedures for experimental purposes10.4103/jpbs.JPBS_175_19 ↗
29. Sporopollenin exine capsules (SpECs) derived from Lycopodium clavatum provide practical antioxidant properties by retarding rancidification of an ω-3 oil10.1016/j.indcrop.2020.112714 ↗
30. Hollow pollen shells to enhance drug delivery10.3390/pharmaceutics6010080 ↗
31. Sporopollenin microcapsule: sunscreen delivery system with photoprotective properties10.3390/pharmaceutics14102041 ↗
32. Alkaloids used as medicines: structural phytochemistry meets biodiversity-an update and forward look10.3390/molecules26071836 ↗
33. The Lycopodium alkaloids10.1016/S1099-4831(05)61001-2 ↗
34. Kaur R., Arora S. Alkaloids-important therapeutic secondary metabolites of plant origin. In 2015.
35. Natural products in drug discovery: advances and opportunities10.1038/s41573-020-00114-z ↗
36. Recent progress in total synthesis of lycopodium alkaloids10.5059/yukigoseikyokaishi.73.1072 ↗
37. Lycopodium alkaloids: pharmacology
38. Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology10.1007/s11101-014-9384-y ↗
39. Recently isolated lycodine-type Lycopodium alkaloids and their total synthesis: a review10.1186/s43094-020-00108-z ↗
40. The Lycopodium alkaloids10.1039/b409720n ↗
41. Lycopodine from Lycopodium clavatum extract inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation10.1016/j.ejphar.2009.09.033 ↗
42. Lycopodine triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in androgen sensitive and refractory prostate cancer cells without modulating p53 activity: signaling cascade and drug-DNA interaction10.1016/j.ejphar.2012.10.041 ↗
43. Appraisal of anti-inflammatory potential of the clubmoss, Lycopodium clavatum L10.1016/j.jep.2006.07.018 ↗
44. Epidemiology of prostate cancer10.14740/wjon1191 ↗
45. 5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapy10.1093/abbs/gmt064 ↗
46. Androgen receptor involvement in the progression of prostate cancer10.1677/erc.0.0100209 ↗
47. Components and anti-HepG2 activity comparison of lycopodium alkaloids from four geographic origins10.1155/2016/4631843 ↗
48. Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases10.3389/fphys.2020.00694 ↗
49. The neglected significance of “antioxidative stress10.1155/2012/480895 ↗
50. Oxidative stress: harms and benefits for human health10.1155/2017/8416763 ↗
51. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy10.1038/s41573-021-00233-1 ↗
52. Investigation of the in vitro and ex vivo acetylcholinesterase and antioxidant activities of traditionally used Lycopodium species from South America on alkaloid extracts10.1016/j.jep.2011.10.042 ↗
53. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease10.1038/s41583-019-0132-6 ↗
54. Oxidative stress in alzheimer's disease: a review on emergent natural polyphenolic therapeutics10.1016/j.ctim.2019.102294 ↗
55. An overview on natural cholinesterase inhibitors–a multi-targeted drug class–and their mass production10.2174/138955711796575434 ↗
56. Chapter 16 - Cholinesterase Inhibitors
57. The efficacy and safety of Alzheimer's disease therapies: an updated umbrella review10.3233/JAD-215423 ↗
58. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis10.1155/2014/363985 ↗
59. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: a network meta-analysis10.1097/MD.0000000000016091 ↗
60. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development10.1124/jpet.102.041616 ↗
61. Cholinesterase inhibitors for Alzheimer's disease
62. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat10.1002/jnr.490240220 ↗
63. Huperzine–a improved animal behavior in cuprizone-induced mouse model by alleviating demyelination and neuroinflammation10.3390/ijms232416182 ↗
64. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine10.1111/j.1745-7254.2006.00255.x ↗
65. Effect of Huperzine A on Aβ-induced p65 of astrocyte in vitro10.1080/09168451.2016.1222265 ↗
66. Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer's disease10.1186/s13041-019-0525-5 ↗
67. Wnt Signaling deregulation in the aging and Alzheimer's Brain
68. Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid-β (Aβ)(42) peptides10.1111/jnc.13873 ↗
69. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes10.1097/00005072-199909000-00011 ↗
70. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis10.1038/27208 ↗
71. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain10.1523/JNEUROSCI.1381-04.2004 ↗
72. Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model10.1038/npp.2010.245 ↗
73. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells10.1016/j.neulet.2004.01.055 ↗
74. Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells10.1002/pmic.201200437 ↗
75. Huperzine A protects neural stem cells against Aβ-induced apoptosis in a neural stem cells and microglia co-culture system
76. Nerve growth factor and Alzheimer's disease10.1515/REVNEURO.1994.5.3.179 ↗
77. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias10.1159/000089137 ↗
78. Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells10.1111/j.1745-7254.2005.00130.x ↗
79. Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production10.1016/j.ejphar.2005.06.026 ↗
80. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease10.1016/S0169-328X(02)00488-6 ↗
81. Ferrer · Brain Pathol. · 2001 · 11 · 14410.1111/j.1750-3639.2001.tb00387.x ↗
82. The role of mitogen-activated protein kinase pathways in Alzheimer's disease10.1159/000067426 ↗
83. Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease10.3233/JAD-131076 ↗
84. Huperzine A alleviates oxidative glutamate toxicity in hippocampal HT22 cells via activating BDNF/TrkB-dependent PI3K/Akt/mTOR signaling pathway10.1007/s10571-015-0276-5 ↗
85. Brain-derived neurotrophic factor: a connecting link between nutrition, lifestyle, and Alzheimer's disease
86. Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects10.2165/11534530-000000000-00000 ↗
87. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice10.1016/S0896-6273(00)80140-3 ↗
88. Neurochemical dissection of synaptic pathology in Alzheimer's disease10.1017/S1041610298005110 ↗
89. Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice10.1002/jnr.22775 ↗
90. Huperzine A: a promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease10.1016/j.mehy.2016.12.006 ↗
91. The soluble extracellular fragment of neuroligin-1 targets Aβ oligomers to the postsynaptic region of excitatory synapses10.1016/j.bbrc.2015.08.107 ↗
92. Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease10.1186/1750-1326-5-4 ↗
93. Huperzine A and its neuroprotective molecular signaling in Alzheimer's disease10.3390/molecules26216531 ↗
94. Huperzine A: is it an effective disease-modifying drug for Alzheimer's disease?10.3389/fnagi.2014.00216 ↗
95. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease10.3389/fnagi.2021.617588 ↗
96. Coenzyme A-dependent tricarboxylic acid cycle enzymes are decreased in Alzheimer’s disease consistent with cerebral pantothenate deficiency10.3389/fnagi.2022.893159 ↗
97. Functional mitochondria are required for amyloid beta-mediated neurotoxicity10.1096/fj.00-0561fje ↗
98. Huperzine a attenuates mitochondrial dysfunction in β-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism10.1002/jnr.20791 ↗
99. ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice10.1016/j.neurobiolaging.2019.05.016 ↗
100. Decreased accumulation of subcellular amyloid-β with improved mitochondrial function mediates the neuroprotective effect of huperzine A10.3233/JAD-2012-120274 ↗